NASDAQ · NRXP
NRx Pharmaceuticals, Inc.
$2.66-$0.03 (-1.12%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
Loading market information…
NASDAQ · ACET · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Adicet Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Adicet Bio, Inc.’s forward annual dividend is $0.04 per share, paid quarterly. The forward yield is 1.12% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Adicet Bio, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$1.56. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Adicet Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 |
|---|
| Mar 6, 2025 |
| -$5.12-1,322.22% vs estimate |
| $0.00-100.0% vs estimate |
| Q3 2024 | Nov 6, 2024 | -$5.44+0.15% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $27.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.66-$0.03 (-1.12%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
$2.68+$0.01 (+0.37%)
Adagene Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.74% below the high.
$1.76-$0.03 (-1.68%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.03% below the high.
$1.19-$0.01 (-0.42%)
Gain Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.58% below the high.
$1.17-$0.06 (-4.88%)
Lite Strategy, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.23% below the high.
$1.75-$0.46 (-20.81%)
CervoMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.5% below the high.
